Tango Therapeutics plans pivotal vopimetostat trial in second-line pancreatic cancer
Apr 19, 2026
Tango Therapeutics said it plans to start a pivotal 300-patient randomized vopimetostat trial in second-line pancreatic cancer this year after FDA interactions. The company also reported early combination enrollment with daraxonrasib and zoldonrasib and said more monotherapy and combination data are expected later this year.